Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Cardio > Pharmacotherapy of Dysrhythmias > Flashcards

Pharmacotherapy of Dysrhythmias Flashcards

(69 cards)

Start Studying
1
Q

symptoms of dysrhythmias

A

palpitations, chest pain, fatigue, dyspnea, lightheadedness, syncope, CHF exacerbation, embolic complication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

types of supraventricular arrhythmias

A

AFib, AFL, atrial tachycardia, AVNRT/SVT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pathophysiology of AFib

A

multiple small reentrant atrial circuits, automaticity, atrial remodeling, irregularly irregular HR/rhythm, loss of atrial contribution to ventricular filling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

risk factors for AFib

A

drugs (caffeine, stimulants), alcohol, smoking, obesity, MI, diabetes, HTN, age, etc etc etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

complications of AFib

A

stroke, heart failure, mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

_____ AFib terminates spontaneously of with intervention within 7 days of onset

A

paroxysmal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

____ AFib is continuous AFib sustained > 7 days

A

persistent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

______ AFib lasts greater than 12 months

A

long-standing persistant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

____ AFib involves a joint decision btwn patient and clinician to stop further attempts to restore/maintain normal sinus rhythm

A

permanent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

_____ AFib is AFib in the absence of rheumatic mitral stenosis, mechanical or biprosthetic heart valve, mitral valve repair

A

non-valvular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

AFib treatment goals

A

prevent thromboembolism, control ventricular rate, convert to and maintain NSR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how do you consider rate vs rhythm control

A

consider patient-specific factors: age, activity level, severity of symptoms: if AFib identified early, pursue rhythm control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

consider rhythm control when…

A

patient preference, HFrEF, recent AFib diagnosis, high burden AFib, younger, failed rate control, worsening HF symptoms with AFib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

consider rate control when…

A

patient preference, longstanding AFib, low burden AFib, severe LA dilation, NYHA III-IV, failed previous rhythm control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

is there a difference in outcome between lenient and strict rate control

A

no

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

when to use lenient rate goal

A

asymptomatic or LVEF >40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what is the lenient rate goal

A

<110 bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

when to use strict rate goal

A

symptomatic or LVEF<40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what is the strict rate goal

A

<80 bpm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

agents to use for rate control

A

beta blockers/ verapamil/ diltiazem preferred, digoxin, amio (caution potential for cardioversion, stroke risk if pt is not anticoagulated)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

when would digoxin or amio be preferred for rate control

A

in decompensated heart failure (LVEF <40%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

metoprolol dosing for rate control

A

2.5-5 mg IV bolus, up to 3 doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

diltiazem dosing for rate control

A

0.25 mg/kg IV bolus, 5-15 mg/hr infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

amio dosing for rate control

A

150 mg IV bolus, 0.5-1 mg/kg infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
what is DCCV
direct current cardioversion
26
meds used to enhance success of conversion by shock, and prevent immediate recurrence
flecainide, propafenone, amiodarone, ibutilide, dofetilide
27
echo-guided cardioversion
ensure no clot !!! can't pursue rhythm control until you know there's no clot--> clots can embolize if you shock and do rhythm control
28
pharmacologic agents for cardioversion
flecainide, propafenone, amiodarone, sotalol, dofetilide, ibutilide
29
flecainide dosing for cardioversion
200-300 mg PO
30
propafenone dosing for cardioversion
600 mg PO
31
amio dosing for cardioversion
IV bolus 150 mg over 1 hr. then cont infusion @ 1 mg/min x 6 hours. then infusion of 0.5 mg/min x 18 hours. then convert to PO: 400 mg bid or tid (7-10 days) until total loading dose of 10 grams reached
32
what agents are used for the "pill in the pocket" method
flecainide, propafenone
33
pearls for "pill in the pocket" method
low-access, rural areas, clearly symptomatic AFib, must be trialed in monitored setting first
34
pharmacologic agents for maintenance of NSR
flecainide, propafenone, amiodarone, sotalol, dronedarone, dofetilide
35
amio dosing for maintenance of NSR
200 mg daily
36
dronedarone dosing for maintenance of NSR
400 mg bid
37
dofetilide dosing for maintenance of NSR
125-500 mcg bid
38
flecainide dosing for maintenance of NSR
50-150 mg bid
39
propafenone dosing for maintenance of NSR
150-300 mg tid or 225-425 mg bid
40
sotalol dosing for maintenance of NSR
80-160 mg bid
41
general monitoring for antiarrhythmics
proarrhythmias (any antiarrhythmic can be proarrhythmic), QTc (class IA, III), potassium, magnesium, kidney function (sotalol, dofetilide, DOACs), left ventricular function
42
special considerations for dofetilide
must be initiated in-patient: monitor QTc, kidney function (CrCL), adjust dose accordingly, monitor for minimum of 3 days
43
dofetilide drug interactions
CYP3A4: verapamil, ketoconazole, trimethoprim, HCTZ
44
contraindications with dofetilide
CrCL <20 mL/min, QTc > 440 msec
45
what to monitor with amio
chest xray, pulmonary function, liver function, thyroid function (T4, TSH), opthalmologic, ECG
46
drug interactions with amiodarone and dronedarone
digoxin and warfarin (cut dose in half), other anti-dysrhythmics, beta blockers, calcium channel blockers, statins (dose cap w/ simva and lova), QTc prolonging drugs, CYP3A substrates/inhibitors/inducers
47
special considerations for digoxin
not first line, narrow therapeutic window, risk of toxicity (age, frailty, renal insufficiency), monitor serum drug concentrations
48
therapeutic anticoagulation is required for ___ before and ___ after cardioversion
3 weeks before and 4 weeks after. exception: can perform cardioversion sooner if echo is performed to rule out presence of clot
49
left atrial occlusion device
for patients with contraindications to anticoagulation (traps the clot so it can't escape)
50
ventricular dysrhythmias originate from where
below bundle of His
51
ventricular dysrhythmias are characterized by ___
abnormal QRS, abnormal QT interval
52
non-sustained ventricular tachycardia
less than 3 beats, terminates spontaneously
53
sustained ventricular tachycardia
30 s or requiring termination in < 30 s due to hemodynamic compromise
54
monomorphic ventricular tachycardia
stable, single QRS morphology with each beat
55
polymorphic ventricular tachycardia
changing/multiform QRS morphology with each beat
56
clinical presentation of PVCs
non life-threatening, typically asymptomatic, associated w/ increased risk of mortality
57
clinical presentation of VT
symptoms vary from asymptomatic to pulseless + hemodynamic collapse. faster HR, longer duration, LV dysfunction= more symptoms
58
clinical presentation of VF
hemodynamic collapse, syncope, cardiac arrest
59
how do you know it's torsades
polymorphic ventricular tachycardia characterized by prolongation of QT interval
60
risk factors for drug-induced torsades
bradycardia, using >1 QT prolonging drug, digoxin therapy, female, heart failure, high drug levels, hypokalemia, impaired hepatic drug metabolism, left ventricular hypertrophy, rapid infusion by IV, recent conversion from AFib, QTc > 500 msec, severe hypomagnesemia, treatment w/ diuretics
61
drugs that may cause TdP
antiarrhythmics: quinidine, procainamide, disopyramide, sotalol, dofetilide, ibutilide. anti-infectives (clarithromycin), antiemetics (droperidol), antipsychotics (haloperidol), antidepressants (sertraline), methadone
62
what agents to use for monomorphic VT with no structural heart disease
verapamil or beta blocker
63
what agents to use for monomorphic VT with structural heart disease
procainamide, sotalol, amiodarone
64
what agents to use for polymorphic VT with normal QTc
amiodarone, beta blockers, lidocaine
65
what agents to use for polymorphic VT with long QTc
d/c offending agents, correct lytes, magnesium, lidocaine, pacing, isoproterenol
66
amio dosing for VT
150 mg IV, then infusion (1 mg/min for 6 hours, then 0.5 mg/min for 18 hours), monitor for hypotension/bradycardia/AV block
67
lidocaine dosing for VT
1-1.5 mg/kg IV load, repeat 5-10 min later with 0.5-0.75 mg/kg then maintenance infusion of 1-4 mg/min. monitor for bradycardia and CNS changes
68
procainamide dosing for VT
10-17 mg/kg IV load given as continuous infusion (20 mg/min) then maintenance infusion of 1-4 mg/min. monitor for QRS widening > 50%
69
magnesium sulfate dosing for VT
1-2 gm IV over 15 min, may repeat as needed, may follow w/ infusion of 0.5-1 gm/hr. monitor for hypotension, vasodilation

Cardio (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions